1 Exogenous ATP produces acute and localized pain in humans, and P2X receptor agonists elicit acute nociceptive behaviours in rodents following intradermal administration to the hindpaw. The predominant localization of P2X 3 mRNA in sensory neurones has led to the hypothesis that activation of P2X 3 and/or P2X 2/3 receptors contributes to nociception. 2 The local administration of the P2X receptor agonist, BzATP (100 ± 1000 nmol paw 71 , s.c.) into the rat hindpaw produced an acute (515 min) paw¯inching response that was similar to that observed in the acute phase of the formalin (5%) test. 3 The co-administration of the potent P2X receptor antagonist, TNP-ATP (30 ± 300 nmol paw ) with formalin (1 and 2.5%) into the rat hindpaw also produced signi®cantly greater nociceptive behaviour as compared to formalin alone. 5 The ability of TNP-ATP and cibacron blue to respectively attenuate and enhance nociceptive responses elicited by exogenous BzATP and formalin provide further support for the hypothesis that activation of peripheral P2X 3 containing channels contributes speci®cally to both acute and persistent nociception in the rat.
Introduction
Extracellular ATP, acting at distinct families of ionotropic (P2X) and metabotropic (P2Y) receptors, is an important signalling molecule in excitatory neurotransmission, platelet aggregation, apoptosis, and cellular dierentiation (Ralevic & Burnstock, 1998) . The proposed role of ATP as a neurotransmitter (Burnstock, 1972 ) is supported by observations that ATP is released from sensory nerves (Houlton, 1959) and by subsequent demonstrations that ATP produces fast excitatory potentials in dorsal root ganglionic neurones (Jahr & Jessel, 1983) . These data have led to the hypothesis that ATP, released from a variety of cell types and as a cotransmitter from sympathetic nerves, may be an important mediator of pain signalling (Burnstock, 1996; Burnstock and Wood, 1996) . Consistent with this role, exogenous ATP elicits pain in a human blister base model (Bleehen & Keele, 1977) and produces pain following iontophoretic administration into the human forearm (Hamilton et al., 2000) .
The nociceptive eects of exogenously administered ATP have also been demonstrated in laboratory animals where intradermal administration of P2X receptor agonists, including ATP and a,b-methyleneATP (a,b-meATP), into the rat hindpaw produce acute nociceptive paw¯inching behaviour (Bland-Ward & Humphrey, 1997; Hamilton et al., 1999) and mechanical allodynia (Tsuda et al., 2000) . A selective P2 receptor-mediated increase in ectopic neuronal excitability that is localised to damaged sensory aerents has also been recently reported in rats following chronic constriction nerve injury (Chen et al., 1999) . Both the potency and eectiveness of locally administered P2X receptor agonists to elicit nociceptive responses are increased in situations of peripheral sensitization induced by intraplantar administration of chemical irritants like carrageenan, prostaglandin E2, or formalin (Sawynok & Reid, 1997; Hamilton et al., 1999) . In addition to the peripheral nociceptive actions of P2X receptor activation, stimulation of spinal P2X receptors may also contribute to nociception as indicated by the ability of intrathecally (i.t.) administered P2 receptor agonists to increase sensitivity to acute and persistent noxious stimuli in rodents (Driessen et al., 1994; Tsuda et al., 1999a,b) .
Nociception induced by exogenously administered P2X receptor agonists can be attenuated by systemically administered morphine (Bland-Ward & Humphrey, 1997) , by the local co-administration of putative P2 receptor antagonists (Sawynok & Reid, 1997) , by agonist-induced desensitization of P2X receptors (Bland-Ward and Humphrey, 1997) , and by ablation of small diameter C-®bres (Hamilton et al. 1999) . Interestingly, P2 receptor agonist-induced nociception can also be inhibited by i.t. administration of NMDA receptor antagonists (Tsuda et al., 1999a) . A direct interaction between purinergic and excitatory amino acid systems in mediating nociceptive processing in the spinal cord is further supported by the demonstration that P2X receptor activation can stimulate glutamate release in spinal dorsal horn neurones (Gu & MacDermott, 1997) .
The utility of available purinergic ligands to evaluate the role of individual P2 receptor subtypes in mammalian physiology has been complicated by the susceptibility of P2 receptor agonists to undergo enzymatic degradation, and by the lack of P2 receptor subtype-selective agonists and antagonists (King et al., 1998; Ralevic & Burnstock, 1998) . However, the recent availability of recombinant mammalian P2 receptor subtypes has allowed for the systematic characterization of the pharmacology of speci®c P2 receptor subtypes (King et al., 1998; Bianchi et al., 1999) and led to further clari®cation of the pharmacological selectivity of ligands acting at P2X receptors. For example, 2' and 3'-O-(4-benzoylbenzoyl)-ATP (BzATP), a putative P2X 7 (P 2Z ) receptor (El-Moatassim & Dubyak, 1992) agonist (pEC 50 =5.33) has also been shown to activate potently recombinant human P2X 1 , P2X 3 and P2X 2/3 receptors (pEC 50 values of 8.74, 7.10 and 6.10, respectively) . In addition, 2',3'-O-(2,4,6-trinitrophenyl)-ATP (TNP-ATP), a¯uorescent ATP analogue with antinociceptive actions following i.t. administration in mice (Tsuda et al., 1999a,b) , has been found to be a potent nanomolar antagonist at the recombinant rat P2X 1 , P2X 3 , and P2X 2/3 receptors Lewis et al., 1998; Thomas et al., 1998) . The putative nonselective P2 receptor antagonist, cibacron blue (Reactive blue 2) (Ralevic & Burnstock, 1998) was also recently demonstrated to be a highly selective allosteric enhancer of P2X 3 receptor activation at concentrations lower than are required for P2 receptor antagonism .
Since subtype-selective ligands for the individual P2 receptors have yet to be identi®ed, eorts to elucidate the speci®c P2X receptor subtypes involved in the transmission of nociceptive signals has been largely based on receptor localization and functional studies using immunohistochemical techniques. These studies have shown that both the homomeric P2X 3 and heteromeric P2X 2/3 receptor subtypes are selectively localized to the central and peripheral terminals of small diameter sensory neurones (Chen et al., 1995; Lewis et al., 1995; Vulchanova et al., 1997; . The application of exogenous ATP directly to rat tooth pulp nociceptors elicits P2X 3 -like electrophysiological responses that are consistent with the immunohistochemical localization of P2X 3 receptors on these neurones (Cook et al., 1997) .
Further, recent data has shown that P2X 3 speci®c immunoreactivity is signi®cantly increased in both the injured dorsal root ganglion and in the ipsilateral spinal dorsal horn following chronic constriction injury of the rat sciatic nerve (Novakovic et al., 1999) .
Taken together, the functional and immunohistochemical localization of P2X 3 containing receptors (P2X 3 and/or P2X 2/3 ) on sensory nerves indicates that these P2X 3 containing channels may have a primary role in mediating the nociceptive eects of extracellular ATP. The present studies were conducted to evaluate the ability of peripherally administered TNP-ATP and cibacron blue to dierentially modulate nociception in two animal pain models, P2X receptor agonist-induced acute nociception and a model of chemically-induced acute and persistent nociception, the formalin test (Tjosen et al., 1992; Abbott et al., 1995) . Since BzATP has potent activity at P2X 3 receptors in vitro , the nociceptive eects of intradermal BzATP were compared to those of other P2X receptor agonists and to formalin.
Methods

Subjects
Adult male Sprague-Dawley rats, 230 ± 350 g, (Charles River, Wilmington, MA, U.S.A.) were housed in groups of ®ve per cage and given free access to food and water. Animals were on a 12 h light-dark cycle of 0600 ± 1800 h. Animals were only used once in each experiment. All experimental protocols and animal handling procedures were approved by an institutional animal care and use committee (IACUC).
Nociceptive testing
Nociceptive responses were assessed using procedures previously described for the formalin test of chemicallyinduced persistent pain (Abbott et al., 1995; Tjosen et al., 1992) . Experimentally naive animals were placed in individual plexiglass cages and allowed 30 min to acclimatize to the testing environment. Following this period, animals received subcutaneous injections of either a formalin solution (1, 2.5, 5%), dierent doses of BzATP alone, or in combination with TNP-ATP or cibacron blue, into the dorsal surface of the right hind paw using an insulin gauge (29G1/2) needle. The volume of injection was 50 ml for all treatments. Saline (0.9%) was used as drug vehicle for all experiments. For co-administration studies, all test compounds were combined and administered in a single injection. To assess acute nociception, animals were observed immediately following drug injections and the number of inch behaviours (paw withdrawals) was recorded over a 1-min period. Additional observations were conducted at sequential 5-min intervals during the ®rst 15 ± 20 min following drug injections (Phase I, acute phase of the formalin test). For some experiments, observations began 30 min after formalin injection and continued for 20 min thereafter (Phase II, persistent phase of the formalin test). For each individual experiment, six rats were used in separate experimental and control groups. Mean cumulative ¯inch responses were analysed by analysis of variance and post-hoc comparisons were conducted using Fisher's least signi®cant dierence test (GB-STAT, Dynamics Microsystems, Inc., Silver Spring, MD, U.S.A.). Statistical signi®-cance was determined at P50.05.
Activation of rat P2X 3 and P2X 2/3 receptors in vitro
The recombinant rat P2X 3 and rat P2X 2/3 receptor cDNAs were identical to the previously published sequences used in the in vitro characterization of the pharmacology of the rat homomeric and heteromeric P2X 3 receptors . 1321N1 human astrocytoma cells stably expressing rat P2X 3 , or rat P2X 2/3 receptors were constructed using standard lipid-mediated transfection methods. All cell lines were maintained in D-MEM containing 10% FBS and antibiotics as follows: 300 mg ml 71 G418 for rat P2X 3 containing cells; and 75 mg ml 71 hygromycin and 150 mg ml 71 G418 for rat P2X 2/3 containing cells. Cells were grown at 378C in a humidi®ed atmosphere containing 5% CO 2 .
P2X receptor function was determined on the basis of agonist-mediated increases in cytosolic Ca 2+ concentration as previously described . BzATP (10 mM) and a,b-meATP (10 mM) were used to activate rat P2X 3 and P2X 2/3 receptors, respectively. Brie¯y, a¯uorescent Ca 2+ chelating dye (Fluo-4) was used as an indicator of the relative levels of intracellular Ca 2+ in a 96-well format using a Fluorescence Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, CA, U.S.A.). Cells were grown to con¯uence in 96-well black-walled tissue culture plates and loaded with the acetoxymethylester (AM) form of Fluo-4 (1 mM) in D-PBS for 1 ± 2 h at 238C. Fluorescence data was collected at 1 ± 5 s intervals throughout each experimental run. Concentration response data were analysed using a fourparameter logistic Hill equation in GraphPad Prism (San Diego, CA, U.S.A.). 
Drugs and reagents
Results
Nociceptive effects of P2X receptor agonists
The intradermal administration of BzATP (100 ± 1000 nmol paw
71
) into the dorsal surface of the rat hindpaw produced a dose-dependent paw¯inching response ( Figure 1a ). The magnitude of nociceptive paw¯inching following 1000 nmol paw 71 BzATP was equivalent to that observed following the acute intradermal administration of 5% formalin (Phase I of the formalin test). The duration of this eect was shortlasting with the majority of paw¯inch responses occurring in the ®rst 5-min interval following drug injection. BzATP did not produce a second phase of prolonged nocifensive paw inching behaviour (data not shown) like that which is characteristically observed following intradermal formalin administration (Phase II of the formalin test) (Tjosen et al., 1992; Sawynok & Reid, 1997) . The ability of intradermal BzATP to produce nocifensive behaviour in the rat was supported by the ability of systemically administered morphine to reduce dose-dependently (ED 50 =4 mg Kg 71 , s.c.) BzATP (1000 nmol paw 71 ) induced hindpaw¯inching (data not shown). Other nucleotide agonists including ATP, a,b-meATP, and 2meSATP also produced acute nociceptive paw¯inching (Figure 1b) , but the maximal responses at the doses tested were signi®cantly less than that observed for BzATP. ADP has been previously shown not to activate P2X 3 receptors and intradermal administration of ADP did not produce any nociceptive responding (P40.05).
Antinociceptive effects of TNP-ATP
The novel P2X receptor antagonist, TNP-ATP inhibited potently agonist-stimulated calcium¯ux in 1321N1 cells expressing either the rat P2X 3 or P2X 2/3 receptors ( Table  1) . As has been shown for the human P2X 3 receptor , sequential removal of the terminal phosphate groups signi®cantly reduces antagonist potency at both P2X 3 and P2X 2/3 receptors. In particular, TNP-AMP shows little inhibitory activity at rat P2X 3 receptors at concentrations up to 30 mM.
Co-administration of intradermal TNP-ATP (30 ± 300 nmol paw
71
) with BzATP (1000 nmol paw
) into the dorsal surface of the rat hind paw, produced a signi®cant (P50.05) and dose-dependent reduction in nociceptive paw¯inching behaviour (Figure 2a) . The antinociceptive eects of TNP-ATP appear to be pharmacologically speci®c since coadministration of TNP-AMP with BzATP did not reduce BzATP-induced paw¯inching behaviour. TNP-ATP also was equally eective to attenuate the acute nociceptive eects of a,b-meATP (Figure 2b ). These eects were mediated at a local peripheral site of action since intradermal administration of TNP-ATP into the contralateral paw was ineective in reducing nociception (Figure 2b ).
Co-administration of TNP-ATP with 5% formalin into the dorsal surface of the rat hindpaw also dose-dependently reduced nocifensive behaviours in the acute (Phase I) portion of the formalin test (Figure 3 ). In addition, the antinociceptive eects of TNP-ATP were also evident in the persistent phase (Phase II) of the formalin test where a signi®cant 30% reduction in formalin-induced paw¯inching was observed at both doses (30 and 100 nmol paw 71 ) of TNP-ATP. In agreement with its antinociceptive activity against BzATP, TNP-ATP, but not TNP-AMP, attenuated nociceptive responses in both the acute (Phase I) and persistent (Phase II) components of the formalin test.
Pronociceptive effects of cibacron blue
Consistent with its ability to selectively enhance human P2X 3 receptor activation , cibacron blue produced a concentration-dependent increase in both BzATP (1 mM) and a,b-meATP (10 mM) stimulated calcium¯ux (EC 50 values=580 and 720 nM, respectively) in 1321N1 cells expressing the recombinant rat P2X 3 receptor (Figure 4a) .
Cibacron blue over the concentration range of 0.3 ± 10 mM also enhanced the activation of the rat P2X 2/3 receptor by BzATP (1 mM) and a,b-meATP (10 mM) (Figure 4b ). However, these eects were biphasic with concentrations of cibacron blue greater than 10 mM producing less enhancement of agonist-mediated activation of the P2X 2/3 receptor. Additionally, concentrations of cibacron blue greater than 30 mM antagonized the activation of the rat P2X 2/3 receptor by a,b-meATP. Consistent with these observations, cibacron blue was found to inhibit only ATP-induced activation of the rat P2X 2 receptor (IC 50 =8 mM) (data not shown).
Since speci®c concentrations of cibacron blue were shown to enhance the activation of the rat P2X 3 and P2X 2/3 receptors in vitro, additional studies were conducted to investigate the potential of cibacron blue to facilitate nociception in the rat. Consistent with the data shown in Figure 1b , the intradermal administration of BzATP alone (10 ± 300 nmol paw 71 ) into the rat hindpaw produced a dosedependent increase in nociceptive behaviour (Figure 5a ± d) . The intradermal administration of cibacron blue alone (10 ± 300 nmol paw 71 ) produced only a mild, but statistically signi®cant acute nociceptive response at a dose of 100 nmol paw 71 (Figure 5a ± d) .
The intradermal co-administration of cibacron blue with BzATP into the rat hindpaw produced signi®cant and biphasic eects in nociceptive paw¯inching behaviour relative to the nociceptive eects of BzATP alone ( Figure 5c ). In contrast, the intradermal co-administration of cibacron blue with a high dose of BzATP (300 nmol paw 71 ) produced a dose-dependent inhibition of paw¯inching responses as compared to the nociceptive eects of BzATP alone ( Figure 5d ). As indicated in Figure 6 , the ability of cibacron blue to enhance the nociceptive eects of both BzATP and a,b-meATP was mediated at the local site of administration since cibacron blue administered into the contralateral paw was ineective.
Since intermediate doses of cibacron blue (30 and 100 nmol paw
71
) were found to be most eective in enhancing the nociceptive eects of intradermal BzATP, these doses of cibacron blue were also examined for their ability to enhance nociception in the formalin test. In the acute phase (Phase I) ) with various concentrations of formalin (1, 2.5 and 5%) also produced greater nociception in the acute phase (Phase I) of the formalin test as compared to the eects of formalin alone (Figure 7) . However, these eects appeared to be additive with formalin since a signi®cant interaction between the nociceptive eects of formalin and cibacron blue was not observed (P40.05) (Figure 7) .
During the persistent nociceptive component (Phase II) of the formalin test, intradermal cibacron blue alone did not produce a signi®cant (P40.05) nociceptive response ( Figure  7) . However, co-administration of cibacron blue (30 and 100 nmol paw 71 ) with formalin (1 and 2.5%) produced signi®cantly greater paw¯inching behaviour relative to the nociceptive eects of either formalin or cibacron blue administered alone (Figure 7) . In this persistent portion of the formalin test, cibacron blue signi®cantly potentiated the nociceptive eects of 1% and 2.5% formalin as indicated by a signi®cantly (P50.05) greater than additive interaction between the nociceptive eects of formalin and cibacron blue. At a minimally nociceptive dose of formalin (1%), the pronociceptive eects of cibacron blue were biphasic with 30 nmol paw 71 of cibacron blue producing a signi®cantly larger enhancement of persistent nociception as compared to the higher dose of cibacron blue (100 nmol paw 71 ) ( Figure  7 ). The intradermal administration of 5% formalin produced signi®cantly greater nociception relative to lower doses of formalin, however, co-administration of cibacron blue with this dose of formalin did not produce a further enhancement of paw¯inching behaviour.
The pro-nociceptive enhancing eects of cibacron blue appear to be pharmacologically speci®c since a structurally similar cibacron blue analogue reactive orange which does not allosterically modulate P2X 3 receptor activation , did not produce nociception alone following intradermal administration (30 and 100 nmol paw
) and had no eect on acute or persistent nociceptive paw¯inching when co-administered with formalin (Figure 8 ).
Discussion
The present data demonstrating that the local administration of prototypic P2X receptor agonists produce acute paw inching behaviour is consistent with and extends other recent ®ndings that implicate a role for P2X 3 containing channels in nociception (Bland-Ward & Humphrey, 1997; Dowd et al., 1998; Hamilton et al., 1999) . In particular, the present studies show that a putative P2X 7 receptor agonist, BzATP (El-Moatassim & Dubyak, 1992) , which is in fact a more potent agonist for P2X 3 , and P2X 2/3 receptors , can produce nociceptive responses in the rat that are similar in magnitude to that produced by the acute intradermal administration of 5% formalin. The pattern of in vivo activity for P2X receptor agonists to induce nociception is consistent with previous pharmacological evaluations of prototypic nucleotide agonists to activate recombinant homomeric P2X 3 and heteromeric P2X 2/3 receptors in vitro .
Similar to other reports (Bland-Ward & Humphrey, 1997; Hamilton et al., 1999) , relatively high intradermal doses of the P2 receptor agonists were required to elicit acute nociceptive responses in naive rats. This situation may re¯ect the susceptibility of these agonists to be rapidly degraded in vivo and/or penetrate to sites of action (BlandWard & Humphrey, 1997; Hamilton et al., 1999) . As the present data show, however, intradermal BzATP was a signi®cantly more ecacious nocifensive stimulus as compared to other P2X receptor agonists like a,bmeATP and ATP such that a high dose of BzATP (1000 nmol paw 71 ) produced a similar degree of acute nociceptive behaviour as compared to 5% formalin.
Since the potent P2X receptor antagonist, TNP-ATP may also be rapidly degraded in vivo (Lewis et al., 1997) , the potential antinociceptive eects of TNP-ATP were assessed following peripheral intradermal administration into the rat hindpaw in an attempt to maximize the local concentration of TNP-ATP at a relevant site of action. The present data demonstrate that TNP-ATP, administered locally, can eectively attenuate nociception produced by either exogenously administered P2X receptor agonist (BzATP and a,bmeATP) or formalin. The antinociceptive eects of TNP-ATP appear to be pharmacologically speci®c since the less active analogue, TNP-AMP, was ineective in reducing the nociceptive eects of either BzATP (1000 nmol paw 71 ) or 5% formalin. These antinociceptive eects of intradermal TNP-ATP extend other recent data, demonstrating that the i.t. administration of TNP-ATP blocks acute thermal hyperalgesia produced by i.t. administration of P2X receptor agonists (Tsuda et al., 1999b) and reduces acute nociception produced by intradermally administered formalin and capsaicin (Tsuda et al., 1999b) .
The ability of TNP-ATP to attenuate dose-dependently acute nociception produced by either BzATP or formalin was similar. Additionally, the antinociceptive eects of peripherally administered TNP-ATP were also evident during the persistent portion (Phase II) of the formalin test. This latter result contrasts with a recent report indicating that i.t. administration of TNP-ATP attenuates Phase I, but not Phase II, nociception in a murine formalin test regardless of whether TNP-ATP administration occurred before or after formalin administration (Tsuda et al., 1999b) . However, another more stable P2 receptor antagonist, PPADS, was equally eective in reducing nociception in both phases of the formalin test following i.t. administration (Tsuda et al., 1999b) , further supporting the idea that TNP-ATP may have a short half-life in vivo. The ability of peripherally administered TNP-ATP to attenuate formalin-induced persistent nociception in the present study may also have resulted from the use of signi®cantly higher doses as compared to the doses used for i.t. administration (Tsuda et al., 1999b) . Taken together, these results suggest that activation of both peripheral and spinal P2X receptors may contribute to the expression of nociception following tissue injury. Further, the ability of intradermal TNP-ATP to attenuate paw¯inching in the formalin model indicates that activation of peripheral P2X receptors contributes to nociception in both the acute aerent barrage and persistent central sensitization phases of this model (Coderre & Melzack, 1992) .
Since TNP-ATP is a potent antagonist that is selective for the P2X 1 , P2X 3 and P2X 2/3 receptors as compared to other P2X receptors (Lewis et al., 1998) , the analgesic actions of TNP-ATP against both BzATP and formalin induced nociception support a role for the activation of these P2X receptor subunits in nociceptive signalling. There is evidence that P2X 3 and P2X 2/3 receptors are localized to peripheral and central processes of sensory aerent nerves and P2X 3 and P2X 2/3 responses are present on dorsal root ganglion neurones . However, signi®cant involvement of P2X 1 receptors in nociceptive signalling does not appear likely since P2X 1 mRNA is not highly expressed in dorsal root ganglion neurones (Lewis et al., 1995; Kidd et al., 1995; Collo et al., 1996) , P2X 1 -mediated electrophysiological responses are not detected in rat dorsal root ganglion neurones (Rae et al., 1998) , and i.t. administration of a putative P2X 1 selective agonist, b,g-(l)-meATP does not produce thermal hyperalgesia in rats (Tsuda et al., 1999a) .
A speci®c contribution of P2X 3 containing channels to the nociceptive eects of exogenously administered P2X receptor agonists and formalin is indicated further by the present demonstration that cibacron blue can selectively enhance the nociceptive eects of these agents. Previous work has shown that cibacron blue selectively enhances human P2X 3 receptor activation by increasing agonist potency and ecacy, as well as facilitating receptor resensitization following acute agonistinduced desensitization . In the present studies, the ability of cibacron blue to enhance agonist activation of the rat P2X 3 receptor in vitro was essentially identical to its allosteric eects on the human P2X 3 receptor . Additionally, the present data show that cibacron blue also enhances agonist activation of the rat heteromeric P2X 2/3 receptor in vitro. However, the allosteric eects of cibacron blue on rat P2X 2/3 receptors are complex in that biphasic enhancement of receptor activation was observed as the concentration of cibacron blue was increased. A contribution of homomeric P2X 2 receptors to these biphasic eects appears unlikely since cibacron blue produced similar eects on both BzATP-and a,b-meATP-mediated activation of rat P2X 2/3 receptors and a,b-meATP does not activate P2X 2 receptors (Lewis et al., 1995; Bianchi et al., 1999) . Additionally, cibacron blue has been previously shown not to enhance agonist activation of the human P2X 1 , P2X 2 , and P2X 7 receptors . Thus, cibacron blue, at low micromolar concentrations, is highly selective for enhancing agonist activation of homomeric P2X 3 and heteromeric P2X 2/3 receptors as compared to its nonselective antagonist activity at other P2X receptor subtypes at higher concentrations (Ralevic & Burnstock, 1998; Alexander et al., 1999) .
While the exact reasons for these apparent dierences in the eects of cibacron blue on homomeric P2X 3 and heteromeric P2X 2/3 receptors in vitro remain unclear, the intrinsic antagonist properties of cibacron blue (Ralevic & Burnstock, 1998 ) may be more pronounced for the P2X 2/3 receptor as compared to the P2X 3 receptor. In this regard, the allosteric eects of cibacron blue are analogous to pharmacological actions of other allosteric modulators. For example, the selective allosteric enhancer of adenosine A 1 receptors, PD 81,723 also shows intrinsic antagonist properties at high concentrations (Bruns & Fergus, 1990; Linden, 1997; Jarvis et al., 1999) . Regardless, both the in vitro and in vivo data are consistent in that the allosteric enhancement eects of cibacron blue on P2X 3 and P2X 2/3 receptors are manifested at speci®c concentrations (and doses). At higher concentrations (and doses), the allosteric eects of cibacron blue are minimised and/or receptor antagonism may predominate due to its intrinsic and nonselective P2 receptor antagonist properties (Ralevic & Burnstock, 1998) . The pronociceptive eects of cibacron blue in vivo appear to be pharmacologically speci®c since another anthraquinone sulphonic acid derivative, reactive orange, which does not alter P2X 3 receptor function , did not enhance the nociceptive eects of intradermal formalin.
The pronociceptive eects of cibacron blue may also depend on the nociceptive state of the animal. Speci®cally, the ability of cibacron blue to enhance BzATP-induced nociception was optimal at an intermediate dose of 30 nmol paw
71
. This dose of cibacron blue was also found to potentiate signi®cantly the persistent nociceptive eects of intradermal 1% and 2.5% formalin. Higher doses of cibacron blue produced less enhancement and/or antagonism of nociception induced by high doses of BzATP. Cibacron blue was also ineective in enhancing the persistent portion (Phase II) of the standard (5%) formalin test. These data suggest that under situations where the intradermal nociceptive stimulus engenders a high rate of nocifensive paw¯inching behaviour, the ability of cibacron blue to provide a further increase in the nocifensive behaviour may be reduced.
The ability of cibacron blue to enhance the nociceptive responses produced by the local administration of an exogenous P2X receptor agonist, or formalin, coupled with the ability of TNP-ATP to attenuate eectively the nociceptive eects of these noxious stimuli, provides further pharmacological evidence that activation of both the homomeric P2X 3 and heteromeric P2X 2/3 receptors contribute speci®cally to pain signalling. The present data, however, do not directly address the relative contributions of each of these P2X 3 -containing channels to the initiation and maintenance of nociception. Since both receptors share a highly similar pharmacological pro®le , delineation of speci®c nociceptive contributions by each receptor subtype has been based on functional responses. Demonstrations that P2X receptor-mediated nociceptive responses can undergo agonist-induced desensitization may indicate that such responses are mediated by the fast desensitizing P2X receptor subtypes, such as the P2X 3 receptor (Bland-Ward & Humphrey, 1997; Tsuda et al., 1999) . A recent report has demonstrated that nociceptive paw inching induced by P2X receptor agonists and formalin are mediated by capsaicin-sensitive C-®bre neurones that predominately express fast-desensitizing P2X 3 -like currents in response to ATP (Tsuda et al., 2000) . Interestingly, this study also showed that local injection of P2X receptor agonists into the rat paw produced tactile allodynia that was mediated by capsaicin-insensitive medium-sized neurones that express predominately slow-desensitizing P2X 2/3 -like currents (Tsuda et al., 2000) . These ®ndings suggest that the pharmacological actions of TNP-ATP and cibacron blue in modulating acute nociceptive paw¯inching behaviour may be mediated predominately by speci®c actions at homomeric P2X 3 receptors localized to small diameter nociceptors. However, both P2X 3 and P2X 2/3 receptor activation may mediate longer-lasting nociceptive responses, as well as nociception involving mechanical hyperalgesia and allodynia (Tsuda et al., 2000) . Further clari®cation of the relative roles of P2X 3 and P2X 2/3 receptors in these nociceptive responses will be dependent on the development of ligands that show pharmacological selectivity between the homomeric and heteromeric P2X 3 containing channels.
